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A new international statement defines usual interstitial pneumonia (UIP) which is a histological and radiological
form of idiopathic pulmonary fibrosis (IPF) more precisely than previously. In the diagnosis of IPF, either in high
resolution computed tomography (HRCT) a UIP pattern must be present or alternatively specific combinations of
HRCT and surgical lung biopsy findings can be accepted. In about two third of the cases IPF can be diagnosed by
clinical and radiological criteria. Thus surgical lung biopsy is needed in about one third of cases to achieve the
ultimate diagnosis, which requires multidisciplinary cooperation. In large clinical trials conducted during the last
decade, lung biopsy was performed in about 30–60% of the cases. The most serious complication of lung biopsy is
mortality within 30 days after the procedure, with a frequency of about 3–4% reported in most studies. Because of
the histological variability, surgical lung biopsy should be taken from a minimum of two lobes. The number of
fibroblast foci in surgical lung biopsy has been shown to correlate with survival in several studies.
Keywords: Fibroblast focus, Complication, Non-specific interstitial pneumonia, Open lung biopsy, Usual interstitial
pneumonia, Video-assisted thoracoscopyReview
Until recently, surgical lung biopsy (SLB) has been
regarded as the golden standard in the diagnosis of
idiopathic pulmonary fibrosis (IPF) and other types of
idiopathic interstitial pneumonias (IIP). During the past
decades, the pathological and clinical terms for the IIPs
have been at least partly different which has been respon-
sible for misinterpretations between different specialists
working with the patients with IIP.
The new international statement on the diagnosis and
management of IPF has recommended adopting a multi-
disciplinary approach for the ultimate diagnosis [1]. On
the other hand, when a patient has a clinically and radio-
logical typical usual interstitial pneumonia (UIP) with no
known causes, the diagnosis can be made without bron-
choscopy, transbronchial biopsy (TBB), bronchoalveolar
lavage (BAL) or SLB procedures. Thus the role of the tra-
ditional investigative methods including SLB is currently
changing. When previously, SLB has been performed as aCorrespondence: riitta.kaarteenaho@kuh.fi
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reproduction in any medium, provided the orbasic diagnostic tool for investigating a patient with
suspected IPF, it is nowadays needed for the ultimate diag-
nosis of the non-typical IPF patients who do not fulfill the
precise criteria for UIP in high-resolution computed
tomography (HRCT) [2,3]. These non-typical IPF patients
may have confounding aspects and other diseases, which
can complicate the diagnostics. In this review article, the
current histological criteria of UIP will be outlined as well
the current awareness of the necessity, commonality and
risks of SLB. The accuracy of histological diagnosis, the
variability of the histological features and the significance
of SLB as a prognostic tool are also discussed.Role of histological diagnostics in the 2011
international statement of IPF
In a new statement, IPF is defined as a progressive inter-
stitial pneumonia of unknown cause, occurring in adults,
limited to the lungs and associated with the histological
and/or radiological pattern of usual interstitial pneumonia
(UIP). In the diagnosis of IPF, other known causes must
be excluded, in HRCT, a UIP pattern must be present, or
specific combinations of HRCT and SLB findings can be
accepted. Further, there are no longer the so-called major
or minor criteria present in the previous guidelines, andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the case in the statement released in 2000 [1,4].
The new diagnostic criteria for radiology and histo-
pathology are more precise than previously and now
include 3 HRCT categories and 4 histological categories,
namely 1) UIP, 2) possible UIP and 3) inconsistent with
UIP for HRTC, and 1) UIP, 2) probable UIP, 3) possible
UIP and 4) not UIP for histopathology. The histological
categories are presented in detail in Table 1. In the
typical UIP pattern, a marked fibrosis, a patchy involve-
ment and fibroblast foci (FF) should be present (Figure 1).
The 2011 statement recommends adoption of the
following diagnostic algorithm for patients with suspected
IPF [1]. Patients should be carefully evaluated for iden-
tifiable causes of interstitial lung disease (ILD). In the
absence of an identifiable cause for ILD, an HRCT de-
monstrating a UIP pattern is diagnostic of IPF. In the
absence of a UIP pattern, and presence of possible UIP or
not UIP features in HRCT, SLB should be performed after
which IPF can be diagnosed by the examining combi-
nation of HRCT and histological patterns. The accuracy of
the diagnosis of IPF has been shown to be increased if one
conducts multidisciplinary discussions with other ILD
experts [5].
How often SLB is performed?
The study of Raghu et al. indicated that IPF can be diag-
nosed by clinical and radiological criteria in about two
third of all cases [6]. Subsequent studies have later
confirmed that the characteristic HRCT features are
absent in around 30% to 40% of IPF patients and thus,
in about 1/3 of IPF patients SLB may be needed to
achieve an accurate diagnosis [7-11]. Hunninghake and
co-authors found that an expert panel of pathologists
was more accurate in making a diagnosis of IPF than aTable 1 Histopathological criteria for UIP/IPF [1]
1. UIP pattern (All four criteria) 2. Probable UIP pattern
1. Marked fibrosis/architectural distortion, ±




2. Presence of patchy involvement of
lung parenchyma by fibrosis
2. Absence of either patchy
involvement or fibroblast
foci, but not both
3. Presence of fibroblast foci 3. Absence of features
against a diagnosis of
UIP suggesting an alternate
diagnosis (see fourth column
4. Absence of features against a




4. Honeycomb changes only
Abbreviations:
IPF idiopathic pulmonary fibrosis.
UIP usual interstitial pneumonia.panel of radiologists and clinicians, and moreover, that
accuracy was higher among the groups of experts than
that for referral centers [8]. Another study revealed that
the accuracy of the diagnosis of IPF increased with
clinical, radiologic, and histological correlation [5].
The most common differential diagnostic problem is
nonspecific interstitial pneumonia (NSIP). Flaherty and
co-authors claimed that patients with an HRCT pattern
of UIP are likely to exhibit a histological pattern of UIP,
but the patients with an HRCT pattern other than UIP
may have either histological UIP or NSIP in the SLB
specimen, and that HRCT has limited specificity in
identifying histological proven NSIP [7]. Silva and others
observed that in 28% of the biopsy-proven NSIP cases,
the HRCT features that were originally suggestive for
NSIP changed to findings that were indicative of IPF
[12]. Although CT features are typical for UIP in most
case, sometimes CT findings may mimic NSIP, chronic
hypersensitivity pneumonitis (HP) or sarcoidosis [13].
Some studies have revealed that HRCT may permit a
distinction between NSIP and IPF in about 70% of
patients [14,15]. However, a recent study showed, that
the characteristic HRCT features of chronic HP, IPF and
NSIP allow one to make a confident differentiation
between these entities in approximately 50% of the
patients [16].
There are some published data about the frequency of
SLB in different countries, which have shown the actual
incidence of SLB in routine clinical diagnostics during
the 1990’s and 2000’s. Epidemiologic studies in Italy,
Belgium, Greece, Spain, United States and Finland have
revealed that the diagnosis has been confirmed by SLB
in 28–38% of the cases [17-22]. Questionnaire-based
national surveys have shown that in Greece and Spain ap-
proximately 31% of the patients with IPF were diagnosed3. Possible UIP pattern
(All three criteria)
4. Not UIP pattern
(Any of the six criteria)
1. Patch or diffuse involvement of





2. Absence of other criteria for





3. Absence of features against a





6. Other features suggestive of
an alternate diagnosis
Figure 1 Histopathological findings of a surgical lung biopsy sample. A. An image showing histological features of usual interstitial
pneumonia (UIP) including dense fibrosis, fibroblast foci (arrows) and only a few nearly normal looking alveolar walls (on the middle).
B. Fibroblast foci (arrows) are seen at higher magnification. Haematoxylin-eosin (HE) stain.
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the past decade, the current diagnostic criteria for IPF
have been used which may provide some enlightenment
on the frequency of SLB. In the Japanese studies exami-
ning pirfenidone, about 20–30% the IPF patients were
biopsied. In contrast in the Capacity studies, the numbers
of SLBs were much higher, with about 40–60% of biopsied
patients (Table 2) [23-25]. The percentages of the SLBs
were similar in the IFIGENIA and also in the first large
interferon-study [26,27]. Furthermore, a high percentage
of biopsies was encountered in the studies of INSPIRE,
BUILD-1, imatinib and etanercept [28-31]. In the study of
triple-kinase, the percentages of SLB were lower, by
approximately 30% (Table 2) [32].
Comparison of video-assisted thoracoscopic
operation and open lung thoracotomy for SLB
Several studies have shown that SLB taken by either open
lung thoracotomy (OLB) or video-assisted thoracoscopic
surgical (VATS) operation is an efficient diagnostic pro-
cedure for ILD [33-36]. Mouroux et al. compared the
efficacy and safety of VATS and OLB in the diagnosis of
ILD and revealed that in conjunction with compatible effi-
cacy and similar morbidity and mortality, VATS offered
several advantages such as reduction of the operative time
and hospital stay [37]. In contrast, in a randomized and
controlled trial, it was observed that there were no differ-
ences in outcomes for thoracoscopic and thoracotomic
procedures [38]. The recent statement of IPF stated that
the decision on which procedure to perform in the SLB
needs to be based on individual patient characteristics and
surgical expertise, and whether or not to pursue SLBshould be evaluated depending on the clinical situation of
the individual patient [1].
Risks of SLB procedure
The most common complication of SLB is prolonged
air-leak which occurs in about 6–12% of the cases; other
common complications can be a need for mechanical ven-
tilation, pneumonia, pneumothorax, hemothorax, pleural
effusion, empyema and prolonged ventilation [39-41]. In
an Icelandic study, the general complication rate was 16%
and the 30-day mortality was less than 3 percent [40]. The
most serious complication is mortality within 30 days after
the procedure which is commonly caused by an acute
exacerbation of IPF, a phenomenon that is characterized
by diffuse alveolar damage (DAD) superimposed on UIP
[42]. The detailed mechanisms leading to DAD after the
SLB procedure are not well known. After the first days of
injury DAD is characterized by hyaline membranes,
edema and interstitial acute inflammation, whereas later
during the organizing phase alveolar septal thickening
with loose organizing fibrosis, type II pneumocyte hyper-
plasia, and patchy or diffuse airspace organization exist.
The histological feature of DAD is known to be associated
also with many other lung diseases like acute interstitial
pneumonia (AIP), severe viral lung infections and acute
respiratory distress syndrome (ARDS) [42].
Table 3 lists the studies which have evaluated the
mortality within 30 days after the SLB procedure
[39-41,43-45]. In some studies, the mortality within 90
days was also evaluated. All studies were retrospective
and the number of the patients has been rather low. In
addition to IPF, some other types of ILDs like NSIP and
Table 2 Number of biopsied IPF-patients in the clinical





Pirfenidone 107 - pirfenidone: n = 15/21%
Azuma et al.,
AJRCCM 2005
- placebo: n = 8/23%
Pirfenidone 267 - high dose: n = 26/24%
Taniguchi et al.,
Eur Respir J 2010
- low dose: n = 16/29%
- placebo: n = 28/27%
Pirfenidone CAPACITY I CAPACITY I
Noble et al., Lancet 2011 435 - 1197 mg: n = 32/37%
CAPACITY I CAPACITY II - 2403 mg: n = 86/49%
CAPACITY II 334 - placebo: n = 85/49%
CAPACITY II
- pirfenidone: n = 94/55%
- placebo: n = 94/54%
Triple-therapy 155 - triple therapy: n = 38/48%
Demedts et al.,
NEJM 2005
- control: n = 35/47%
IFIGENIA - excluded patients: n =24/89%
Interferon gamma-1b 330 - IFN-γ-1b: 62%
Raghu et al., NEJM 2004 - placebo: 67%
Interferon gamma-1b 826 - IFN-γ-1b: n = 305/55%
King et al., - placebo n = 151/55%
Lancet 2009
INSPIRE
Bosentan 158 - bosentan: 68%
King et al., - placebo: 60%
AJRCCM 2008
BUILD-1
Imatinib 119 - imatinib: n = 25/42%
Daniels et al., - placebo: n = 29/48%
AJRCCM 2010
Etanercept 88 - etanercept: n = 28/46%
Raghu et al., - placebo: n = 23/41%
AJRCCM 2008
Triple-kinase 432 - placebo: n = 19/22%
Richeldi et al., - 50 mg × 1: n = 25/29%
NEJM 2011 - 50 mg × 2: n = 27/31%
- 100 mg × 2: n = 20/23%
- 150 mg × 2: n = 29/34%
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diseases (CTD-ILD) have been also included in most of
the studies. The study of Utz and co-authors revealed
the highest mortality, nearly 17% [45]. In that particular
study, in which the patients were operated during the
years 1986–1995, most of the biopsies had been takenby open thoracotomy and less by video-assisted thora-
coscopic operation, while in other studies only a minority
of the patients had been operated by open thoracotomic
surgery. In most of the studies, the mortality was lower
than in that reported by Utz, namely approximately 3–4%
[39,40,43,44]. In the study by Park and co-authors no
difference in mortality between OLB and VATS was
observed, while in another study no mortality in the
patients operated by VATS was observed since all the
patients who had died within 30 days had been operated
by OLB [44]. The number of the SLBs in these studies has
been variable. In the study of Tiitto et al. only one SLB
was taken from most of the patients [44], whereas in some
other studies, the number of the biopsies varied from 2 to
4 with no marked effect on the complication rate or the
short term mortality [39,41]. In the abovementioned stu-
dies, the risk factors for the mortality within 30 days were
the existence of acute exacerbation of IPF at time of
biopsy, low diffusion capacity (DLCO), mechanical venti-
lation, immunologic treatment, OLB and an age of more
than 67 years.
The study of Park et al. showed that SLB performed at
the time of acute exacerbation of IPF resulted in higher
30-day mortality (28.6%) compared to the patients with-
out acute exacerbation (3.0%) [39]. Utz and co-authors
presented in their study that 10 of 68 patients with UIP
died within 30 days after the procedure, when accelerated
decline of the disease was the reason for performing SLB
in 4 (40%) patients [45]. Fibla and others observed that 28
(9%) of 331 patients died within 30 days, of which 9 was
in preoperative intensive care treatment [41]. That par-
ticular study revealed high rate for severe complications
like acute exacerbation for respiratory failure (26.1%) and
postoperative need for intensive care (22.7%).
Because of the retrospective and descriptive nature of
the studies, it is difficult to draw any firm conclusions
on the risk factors or limits for SLB. On the other hand,
it is probable that no controlled clinical trial will be
performed on this particular topic in the future. If one
wishes a more accurate estimation of the risks of SLB,
then larger patient material from multicenter studies
may be required. A new method for performing SLB has
been recently presented, such as awake thoracoscopic
biopsy, which was shown to be feasible requiring only
regional anesthesia and it has resulted in low morbidity,
excellent diagnostic yields, short hospital stays, and low
costs [46].
Accuracy of histologic diagnosis and histologic
variability of SLB
It has been shown that there exists an inter-observer
variability between pathologists when analyzing SLB
samples. The study of Nicholson et al. revealed that
there was only fair agreement among pathologists who
Table 3 Studies of mortality within 30 days after the surgical lung biopsy procedure




Eur Respir J 2001
IPF = 46 OLB 73% No of biopsies not described - 16.7% in total
population
- 4/10 had AE-IPF
before SLB
CTD-UIP = 14 VATS 27% 1986-1995 - All IPF - Lower DLCO
- 21.7% in IPF
Lettieri et al.,
Chest 2005
IPF = 42 OLB (no?) No of biopsies not described - 4.8% - Mechanical ventilation
Non-IPF = 41 VATS (no?) 1996-2002 (5/6%) - Immunologic treatment
- No difference IPF
vs non-IPF, VATS vs OLB
Tiitto et al.,
Chest 2005
IPF = 64 OLB n = 42 1 - OLB 5.3% - OLB
CTD-UIP = 12 VATS n = 34 1973-2002 - VATS 0%
Park et al., Eur J
Cardio-Thorac Surg 2007
IPF = 140 OLB n = 50 2-3 - 4% - AE-IPF




Ann Thorac Surg 2009
UIP = 23 OLB n = 45 1: 70% - 3% - No data of
different ILDs
OP = 17 VATS n = 28 2: 20% (4%)
NSIP = 6 1986-2007 - No difference OLB
vs VATS
Others = 27
Fibla et al., Int J
Cardiovasc Thorac Surg 2012
IPF = 122 OLB 10% 1: 16% VATS 9% - Age > 67
COP = 31 VATS 90% 2: 64% OLB 10.6% - OLB
RBILD = 16 3: 59% - Immunologic treatment
NSIP = 13 4: 1% - No data of
different ILDs
Others = 114 2002-2009
6% in ICU
Abbreviations:
AE-IPF acute exacerbation of idiopathic pulmonary fibrosis.
COP cryptogenic organizing pneumonia.
CTD-ILD connective tissue associated interstitial lung disease.
DLCO diffusion capacity.
ILD interstitial lung disease.
ICU intensive care unit.
IPF idiopathic pulmonary fibrosis.
NSIP nonspecific interstitial pneumonia.
OLB open lung thoracotomy.
RBILD respiratory bronchiolitis and interstitial lung disease.
SLB surgical lung biopsy.
VATS video-assisted thoracoscopic operation.
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the patients [47]. The previous studies analyzing the
inter-observer error among clinicians and radiologists
have shown similar kinds of results [48,49]. The multi-
center study of Thomeer et al. observed a fair agreement
in histological analysis between several investigators,
with those of HRCT analyses were fair to moderate [50].
In that particular study, the lung biopsy material com-
prised of 44 SLB and 38 transbronchial biopsy samples,
which might have had some effect on the result. The
accuracy of diagnosis has been shown to be higher
among expert specialists than the corresponding value
made by physicians in the referring centers [5].Some studies have indicated that the histological
features may be variable in some cases of IPF since in
some lobes or segments of lung NSIP-like features can
exist in addition of UIP features. The patients with the
coexistence of both NSIP and UIP patterns seemed to
behave similarly to those with only a UIP pattern
[51,52]. Sampling errors may result if only one biopsy is
taken since it has been shown that in 26% of the cases,
the histological classification would have been different
between UIP and NSIP if only one biopsy had been
taken. These findings laid the foundation for the current
recommendation that SLB should be taken from a mini-
mum of two lobes, and preferably more [51].
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ever, overlapping features with other types of IIPs and
hypersensitivity pneumonia. Unlike IPF, the prognosis of
NSIP is good and it occurs mostly in middle-aged
women who are never-smokers [53]. At present, the evi-
dence that fibrotic form of NSIP is a precursor of UIP is
weak. Possibly a subset of patients mistakenly diagnosed
as having fibrotic NSIP may ultimately prove to have
IPF. Familial form of IIP has been often called as familial
IPF. A recent study showed, however, that less than half
of the patients with familial IIP had histological strictly
defined UIP features, but rather more often unclassifi-
able fibrosis [54].
SLB as a tool for a marker of prognosis and the
significance of fibroblast foci
In addition of the diagnosis of ILD, SLB can be used also
as source of a biomarker for the prognosis in IPF patients.
The number of fibroblast foci (FF) i.e. active centers of
fibrogenesis consisting of myofibroblasts, fibroblasts and
extracellular matrix (ECM) proteins and lined by regen-
erative hyperplastic or metaplastic alveolar epithelium, has
been shown to correlate with patient survival in several
studies [47,55-59], but not in all [60] (Table 4). The
detailed information of the studies focusing on the num-
ber of fibroblast foci is presented in the Table 4.
Despite this quite convincing evidence, the counting
of FF in biopsies has not yet become a common routine
clinical practice. This might be attributable to the fact
that the number of FF has been evaluated with variable
methods in the different studies. At present FF has
proved to be the only reproducible histological factor
that correlates with the prognosis in IPF. There are very
few studies, which have evaluated the value of immuno-
histochemical markers from SLB specimens on survival,
since during the past decade most studies focusing on
biomarkers have been conducted by using serum or BAL
samples. Nearly two decades ago it was reported that a
high expression level of the ECM protein, tenascin-C as
detected by immunohistochemistry in SLB samples, cor-
related with shortened survival in patients with UIP [61].
Transbronchial biopsy in the diagnosis of IPF
Neither the previous nor the current statement has
recommended TBB for the diagnosis of IPF; this tech-
nique has been used mainly to exclude other ILDs such
as sarcoidosis, or malignancies and infections [1,4]. The
study of Berbescu et al. however showed that characte-
ristic histologic features of UIP could be identified from
TBB specimens more often than previously appreciated
observing changes diagnostic of UIP in 43% of the cases
[62]. Another study showed that TBB could reveal a UIP
pattern in about 30% of the cases [63]. In contrast Shim
and others found UIP features in only 9.4% of thepatients [64]. In a recent review article it was presented
that in the right clinical setting and with appropriate
tissue sampling TBB can support a diagnosis of UIP
fairly often being especially useful in elderly patients or
those with advanced fibrosis in whom there is significant
mortality and morbidity from SBL [65]. It is notable that
TBB samples in the abovementioned studies have been
analyzed by the expert pulmonary pathologists, which
may emphasize the need for refer these cases to the
specialized centers. A previous study showed that by
using a novel technique for TBB, namely transbronchial
cryobiopsy, the size of TBB samples were much larger
than those obtained using forceps [66]. In a recent pro-
spective study TBB cryobiopsy samples obtained from 40
patients were evaluated, of which in 85% of the cases at
least two of three typical UIP features were present [67].
Conclusion
It is probable that approximately one third of the IPF
patients would need SLB in order to obtain an accurate
diagnosis. Several remarkable points should be consi-
dered when making a decision whether or not to per-
form the SLB. The mortality, which can occur shortly
after the procedure, has probably been the major reason
to refrain from performing SLB. The precise risk limits
for complications of SLB procedure are not well known.
Thus a thorough deliberation taking into consideration
age, other diseases, medication, lung function and the
stage of the pulmonary fibrosis are needed before pro-
ceeding to a procedure of SLB. As it has been noted in
the new statement, in patients with severe physiologic
impairment or substantial comorbidity, the risks of SLB
may outweigh the benefits of establishing a secure dia-
gnosis of IPF, and moreover, clinicians must spend
adequate time with patients to discuss patients’ values
and preferences [1].
The accuracy of the histological diagnosis might be
problematic, and thus it seems to be fundamental that
SLB are analyzed by experienced pulmonary patholo-
gists. It is probable that the histological diagnosis may
become even more challenging than previously when
only the patients with non-typical HRCT features are
biopsied, and UIP may be at risk of remaining obscured
by other concomitant diseases or confounding factors.
Moreover, the challenge of pulmonary pathology will be
greater because of the fact that more complex and less
classical lung diseases will be investigated that will make
classification of histological patterns more difficult
and may limit the role of pathology as a routine pre-
dictor of prognosis. Evaluation of the pathological
archives from previous decades might help in the
training of pulmonary pathologists and for gathering
experience from a large amount of samples including
also the typical cases representing IPF/UIP. It is likely
Table 4 Studies of the association between the numbers of fibroblast foci (FF) to the prognosis of IPF
Study Patients and method Results
King et al., Am J Respir Crit Care Med 2001 87 IPF Granulation/connective tissue score i.e. FF
was a significant predictor of survival
in patients with IPFSemiquantitative
Stainings: HE, pentachrome, Prussian
blue and toluidine blue
Nicholson et al., Am J Respir Crit Care Med 2002 53 IPF Mortality of the patients was linked to an
increasing FF score, which associated also
with greater declines in FVC and DLCOSemiquantitative
Staining not described
Flaherty et al., Am J Respir Crit Care Med 2003 99 IPF and 9 with connective tissue
disease (CTD-UIP)
The profusion of FF associated with the
survival of UIP in whole study material,
but not in IPF
Semiquantitative The patients with IPF had higher profusion
of FF than the patients with CTD-UIP
Staining not described
Tiitto et al., Thorax 2006 64 IPF and 12 CTD-UIP The number of FF correlated with the
survival of the patients. The patients
with≤ 50 FF/cm2 had a median survival
of 89 months compared with 49 months
in those with >50 FF/cm2
The total number of FF was counted in
the area of which was defined by image analysis.
The number of FF was divided into two subgroups
(≤ 50 or >50 FF/cm2)
Stainings: AB-PAS and HE The number of FF was lower in
CTD-UIP than in IPF
Enomoto et al., Chest 2006 53 IPF %FF score was a significant predictor
of survival in IPF patients
Images of sections were studied by image analysis. %
FF was calculated by dividing the area of FF by that
of the target field. Overall %FF in each patient was
defined as the average %FF > 10 selected cases
HE staining
Hanak et al., Respir Med 2008 43 IPF No significant relationship between
FF profusion and survival
FF was counted by using a conventional point-
counting technique. The number of points
intersecting FF was expressed as a fraction of the
total points counted on each slide and a mean value
was calculated
Staining not described




AE-IPF acute exacerbation of idiopathic pulmonary fibrosis.
AB-PAS Alcian blues periodic acid Schiff.
COP cryptogenic organizing pneumonia.
CTD-ILD connective tissue associated interstitial lung disease.
DLCO diffusion capacity.
HE haematoxylin-eosin.
ILD interstitial lung disease.
ICU intensive care unit.
IPF idiopathic pulmonary fibrosis.
NSIP nonspecific interstitial pneumonia.
RBILD respiratory bronchiolitis and interstitial lung disease.
OLB surgical lung biopsy taken by thoracotomic surgical operation.
VATS surgical lung biopsy taken bb video-assisted thoracotomic surgical operation.
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NSIP and for the exclusion of IPF, especially after the
preliminary results of the Panther-study which re-
vealed a harmful effect of triple therapy treated IPF
patients [68].Since many IPF patients are at an older age and suffer
from many other diseases, or their lung disease has
already progressed to an advanced stage, SLB cannot be
considered as a safe procedure for all individuals. Thus,
there is a definite need for developing new diagnostic
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to the current statement, BAL or TBB are no longer
required for the diagnosis of IPF. A new BAL guideline
has been recently published [69] as has as a new BAL
cell culture technique for diagnostic samples [70]. Hope-
fully, BAL and TBB will gain greater acceptance in IPF
diagnostics in the future with the development of more
standardized techniques and innovative methodologies.
Improvements in all methodological techniques inclu-
ding radiology and also the invasive procedures such as
SLB, TBB and BAL could be predicted to make the dia-
gnostics of IPF and other type of ILDs not only faster
and safer but also more accurate, which will be im-
portant in the future due to a new classification of IIP
including a category of unclassifiable ILD [71,72].
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